A Randomized, Controlled, Multi-center Phase III Clinical Study of AK112 Plus Nab-paclitaxel Versus Placebo Plus Nab-paclitaxel as First-line Treatment for Locally Advanced Unresectable or Metastatic Triple-negative Breast Cancer
Latest Information Update: 16 Jan 2025
Price :
$35 *
At a glance
- Drugs Ivonescimab (Primary) ; Paclitaxel
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors Akeso Biopharma
- 16 Jan 2025 New trial record